A new Treg player emerges with $46M and backing from Takeda

Nicole DeFeudis

Editor

In recent years, the chorus of biotechs and Big Pharma backers targeting regulatory T cells — also known as “Tregs” — for cancer and autoimmune diseases has …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

A new Treg player emerges with $46M and backing from Takeda

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Pfizer hires ex-FDA deputy Patrizia Cavazzoni as chief medical officer

Pfizer wants in on Summit’s goal to beat Keytruda via ADC combos

Post-Hoc: Pharma CEOs' alternative reality with Trump

Sanofi, Teva bolster case for IBD drug with Phase 2 data, despite potential competition

FDA lifts hold on Entrada's Duchenne drug after two years

How AI can address ongoing challenges in the life sciences industry

A new Treg play­er emerges with $46M and back­ing from Take­da

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

A new Treg player emerges with $46M and backing from Takeda